Mild to Moderate COVID-19
Also known as: Mild, moderate Novel Coronavirus Infectious Disease (COVID-19) / Mild-to-moderate COVID-19
| Drug | Drug Name | Drug Description |
|---|---|---|
| DB15718 | Bamlanivimab | A neutralizing human IgG1κ monoclonal antibody against the SARS-CoV-2 spike (S) protein for use in patients aged 12 and over at high risk of developing severe COVID-19. |
| DB15897 | Etesevimab | Etesevimab in combination with bamlanivimab is used to treat mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients, including neonates, with positive results of direct SARS-CoV-2 viral... |
| DB15940 | Imdevimab | Part of an investigational recombinant monoclonal antibody cocktail used to treat mild to moderate COVID-19. |
| DB15661 | Molnupiravir | An orally bioavailable isopropylester cytidine analog used to treat COVID-19. |
| DB16691 | Nirmatrelvir | An oral protease inhibitor with emergency use authorization for the treatment of mild-to-moderate COVID-19. |
| DB14761 | Remdesivir | A nucleoside analog used to treat RNA virus infections including COVID-19. |
| DB00503 | Ritonavir | An HIV protease inhibitor used in combination with other antivirals in the treatment of HIV infection. |
| Drug | Drug Name | Phase | Status | Count |
|---|---|---|---|---|
| DB00176 | Fluvoxamine | 2 | Suspended | 1 |
| DB00051 | Adalimumab | 3 | Withdrawn | 1 |